Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 5/20 | 0.56 |
| ▸ | POLQ | O75417 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | MLYCD | O95822 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL886825 | 0.85 | KCNA5 (0.56) | KCNA5POLQCYP19A1CYP3A4NOTUM | |
| SCHEMBL1367302 | 0.79 | KCNA5 (0.64) | KCNA5POLQCYP3A4GRM5NOTUM | |
| SCHEMBL2062944 | 0.78 | KCNA5 (0.67) | KCNA5POLQGRM5NOTUM | |
| SCHEMBL1376788 | 0.72 | KCNA5 (0.47) | KCNA5POLQCYP19A1CYP3A4GRM5 | |
| SCHEMBL884806 | 0.72 | KCNA5 (1.00) | KCNA5 | |
| SCHEMBL10094607 | 0.72 | KCNA5 (0.57) | KCNA5GRM5NOTUM | |
| SCHEMBL2062954 | 0.72 | KCNA5 (0.55) | KCNA5POLQGRM5HDAC6NOTUM | |
| SCHEMBL884617 | 0.70 | KCNA5 (0.95) | KCNA5 | |
| SCHEMBL2062668 | 0.69 | KCNA5 (0.51) | KCNA5GRM5NOTUM | |
| SCHEMBL884543 | 0.68 | KCNA5 (0.80) | KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940406-A2 | POTASSIUM CHANNEL INHIBITORS | Merck and Co., Inc. (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007050348-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-05-03 | — | — | WO | disclosed |